

Original Article

Impact of chronic thrombocytopenia on healthcare resource utilization, in-hospital outcomes, and costs following percutaneous coronary intervention of chronic total occlusion: a nationwide propensity weighted analysis

Sheriff N Dodoo¹, Bettye A Apenteng², Alexis K Okoh³, Isaac A Opoku⁴, Ugochukwu O Egolom⁵, Nima Ghasemzadeh⁶, Ronnie Ramadan⁶, Glen Henry⁶, Gregory Giugliano⁶

¹Georgia Heart Institute, Northeast Georgia Medical Center, 743 Spring Street NE, Gainesville, GA 30501, USA;

²Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, 501 Forest Dr, Statesboro, GA 30458, USA; ³Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, 1462 Clifton Way NE, Atlanta, GA 30322, USA; ⁴Department of Internal Medicine, Piedmont Athens Regional Hospital, 1270 Prince Ave, Suite 102, Athens, GA 30606, USA;

⁵Georgia Heart Institute, Northeast Georgia Medical Center, 200 S Enota Dr NE Suite 100, Gainesville, GA 30501, USA; ⁶Georgia Heart Institute, Northeast Georgia Medical Center, 200 S Enota Dr NE Suite 200, Gainesville, GA 30501, USA

Received October 29, 2023; Accepted December 27, 2023; Epub February 20, 2024; Published February 28, 2024

Abstract: Background: Data on the impact of chronic thrombocytopenia (CT) on outcomes following chronic total occlusion (CTO) percutaneous coronary interventions (PCI) is limited. Most studies are case reports and focused on postprocedural thrombocytopenia. The purpose of this present study is to assess the impact of CT (> one year) on health resource utilization (HRU), in-hospital outcomes, and cost following CTO PCI. Methods: We used discharge data from the 2016-2018 National Inpatient Sample and propensity score-weighted approach to examine the association between CT and HRU among patients undergoing CTO PCI. HRU was measured as a binary indicator defined as a length of stay greater than seven days and/or discharge to a non-home setting. The cost was measured as total charges standardized to 2018 dollars. Both outcomes were assessed using generalized linear models adjusted for survey year, and baseline characteristics. Results: Relative to its absence, the presence of CT following CTO PCI was associated with a 4.8% increased probability of high HRU (Population Average Treatment Effect (PATE) estimate = 0.048; 95% Confidence Interval (CI) = 0.041-0.055; P<0.001) and approximately \$18,000 more in total hospital charges (PATE estimate = +\$18,297.98; 95% CI = \$15,101.33-\$21,494.63, P<0.001). Conclusion: Among chronic total occlusion patients undergoing percutaneous coronary intervention, those with chronic thrombocytopenia had higher resource use, including total hospital charges, and worse in-hospital outcomes when compared with those without chronic thrombocytopenia.

Keywords: Chronic total occlusion, healthcare resource utilization, percutaneous coronary intervention

Introduction

Several inflammatory modulators are implicated in the pathogenesis of coronary artery disease. Platelets are vital in the cascade of events leading to acute coronary syndrome [1, 2]. Platelet inhibition is the current therapeutic paradigm for acute coronary syndrome, including percutaneous coronary intervention (PCI)

[3]. Practice guidelines advocate for dual antiplatelet therapy following revascularization of diseased coronary vessels using drug-eluting stents [4]. However, this antiplatelet strategy is associated with an increased risk of bleeding [5], especially for those with chronic thrombocytopenia (CT) [6]. Chronic total occlusion (CTO) of a coronary artery is 100% occlusion of its lumen over a period of more than 120 days (about four

Impact of chronic thrombocytopenia on CTO-PCI

months) with concomitant Thrombolysis in Myocardial Infarction (TIMI) grade 0 flow (true occlusion) or a TIMI grade 1 flow (functional occlusion) [7].

Approximately 15% of patients with CTO of a coronary artery present with unstable angina; others experience chronic stable angina, while most of these patients may be asymptomatic [8]. Patients who remain symptomatic despite maximally tolerated guideline-directed medical therapy may opt for revascularization with PCI using drug-eluting stents [8]. There is a lack of consensus strategy in managing patients with CT. Unfortunately, patients with CT have invariably been excluded from randomized clinical trials of CTO PCI or secondary prevention anti-thrombotic therapies [9]. Ayoub et al. evaluated the clinical impact of CT on in-hospital outcomes following PCI. They found that patients undergoing PCI with CT had a doubled risk of post-procedural bleeding, a higher risk of post-procedural vascular complications, and higher in-hospital mortality when compared to those without CT [10]. This pivotal study included all PCI patients irrespective of their indication for this revascularization strategy. Unfortunately, data on the clinical impact of CT following PCI in CTO patients is lacking. To help fill this void in the appreciation of the safety of PCI in this under-studied CTO population, we hypothesized that chronic thrombocytopenia portends adverse clinical outcomes, including high resource utilization (HRU) and costs in CTO patients when compared to those without thrombocytopenia, using a large all-payer inpatient database.

Methods

Data source

The National Inpatient Sample (NIS) is a publicly accessible database of all-payer discharge data maintained under the auspices of the Agency for Healthcare Research and Quality (AHRQ). The NIS comprises patient-level and hospital-level data from about 8 million hospitalizations and a proportionate sample of 20% of community healthcare facilities in the United States. The NIS sampling methodology allows for applying weights to variables to obtain annual national estimates. NIS has been validated against several hospital-level databases in the United States [11, 12].

Study selection, endpoints, and definitions

The authors queried patient-level and hospital-level discharge data from the NIS database between 2016 and 2018 with a primary or secondary diagnosis of CT, during which PCI was performed on account of CTO (ICD-10-CM codes D696, D6949, D6942, D693, D694, and D6959). CT is a blood platelet count of less than 150,000 cells/ μ l. In the NIS, the CT diagnosis is exacted based on these ICD 10 codes without the exact laboratory values. To select study subjects with CT, we used a chronic indicative variable, which isolated the diagnosis of interest CT that was present at least 12 months from the index hospitalization. The Patients with acute thrombocytopenia in whom or for whom the chronic indicative variable showed that the diagnosis of interest was present for less than 12 months from the index admission were excluded. Those with periprocedural thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulopathy were also excluded.

The primary outcome of interest was HRU, a binary indicator defined as a length of stay greater than seven days or discharge to a non-home setting [13, 14]. Secondary endpoints were In-hospital mortality, vascular complication, mechanical circulatory support, stroke, permanent pacemaker placement (PPM), acute kidney injury (AKI), dialysis, and cost. Cost was adjudicated as total charges obtained from the NIS data standardized to the dollar's value in 2018. These diagnoses were obtained in parallel, as both International Classification of Diseases-10th Edition-Clinical Modification (ICD-10-CM) and clinically meaningful clusters of ICD-10-CM codes, termed Clinical Classification Software codes. Given that the NIS database contained de-identified patient clinical data, the study was exempt from Institutional Review Board approval.

Statistical analysis

We applied weights provided by the NIS to obtain actual annualized estimates of admissions during the study period. To account for the complex sampling of the NIS, we followed the propensity score weighting approach for data as outlined by DuGoff and colleagues [15]. Propensity scores were calculated by estimat-

Impact of chronic thrombocytopenia on CTO-PCI




Figure 1. Study flowchart showing inclusion and exclusion criteria utilized in recruiting the study population. CTO, chronic total occlusion; CT, chronic thrombocytopenia; PCI, percutaneous coronary intervention; GLM, generalized linear model.

ing the probability of having CT as a function of patient-level and hospital-level covariates. The effect of CT on HRU among patients undergoing CTO PCI was then assessed using generalized linear models (GLM) weighted by a combined weight derived from the propensity score and survey weights. HRU was evaluated using a GLM model with binomial distribution and a log link. A GLM model with gamma distribution and a log link was also used to assess total charges. GLM models were also adjusted for the survey year, illness severity, and all the covariates. All analyses were completed in Stata v.17, incorporating primary sampling units and clusters to obtain national estimates. Statistical significance was assessed at $P < 0.05$ using two-tailed tests.

Results

Baseline characteristics and matched cohorts

Two hundred sixteen thousand nine hundred sixty-six (216,966) patients underwent PCI due to CTO during the study duration of 2016 to 2018 (**Figure 1**). After excluding patients with acute thrombocytopenia, periprocedural thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, 216,905 patients were identified and included in the study. CT was present in 7090 patients

(3.3%). Before propensity score weighting, the CT and non-CT groups differed regarding all assessed patient and hospital-level characteristics. Specifically, patients with CT were older (69.2 years vs. 65.1 years; $P < 0.001$), were considered to have a more clinically severe illness (average illness severity score of 3.2 vs. 2.2; $P < 0.001$) and were more likely to have two or more comorbidities (85.1% vs. 66.0%; $P < 0.001$). Patients with CT were also more likely to be male (71.6 vs. 66.0%; $P < 0.001$) and less likely to be Black (9.0% vs. 9.7%; $P < 0.01$). They were more likely to have public insurance (76.3% vs. 64.5%; $P < 0.001$) and reside

in a metropolitan area (83.1% vs. 81.2%; $P < 0.001$), but less likely to have received care at small (12.1% vs. 14.5%; $P < 0.001$), rural hospitals (3.9% vs. 5.5%; $P < 0.001$), and hospitals located in the Northeast region (15.4% vs. 18.0%; $P < 0.001$). They were, however, more likely to be cared for in private non-profit hospital facilities (76.7% vs. 74.9%; $P < 0.01$). The application of propensity score weights balanced the two groups regarding all assessed patient-level and hospital-level covariates (**Table 1**).

Predictors of high resource utilization and total charges

CT during CTO PCI was associated with a higher likelihood of high resource use ($b = 0.212$; 95% CI = 0.191-0.235; $P < 0.001$). Relative to its absence, CT during CTO PCI was associated with an approximately 6.97% increased probability of high resource use (Population Average Treatment Effect (PATE) estimate = 0.0697; 95% Confidence Interval (CI) = 0.0617-0.0776; $P < 0.001$). Patient-level characteristics that independently predicted HRU included female sex compared to male ($b = 0.070$; 95% CI = 0.044-0.097; $P < 0.001$); the other race categories (racial minorities) compared to Non-Hispanic White ($b = 0.048$; 95% CI = 0.007-0.089; $P = 0.023$); public insurance coverage, compared to self-pay or uninsured ($b = 0.187$;

Impact of chronic thrombocytopenia on CTO-PCI

Table 1. Baseline demographic and clinical characteristics of CTO PCI with and without CT before and after application of Propensity weights

| Variables | Before Application of Propensity Weights | | | After Application of Propensity Weights | | |
|---|--|-------------------------------------|---------|---|-------------------------------------|---------|
| | CTO-PCI with CT (n = 7090) | CTO-PCI without CT (n = 209,815) | P value | CTO-PCI with CT (n = 7090) | CTO-PCI without CT (n = 209,815) | P value |
| | Mean (standard error) | Mean (standard error) | | Mean (standard error) | Mean (standard error) | |
| Illness Severity Index | 3.18 (0.009) | 2.22 (0.003) | <0.0001 | 3.06 (0.012) | 3.03 (0.013) | 0.456 |
| | % | % | P value | % | % | P value |
| Sex | | | <0.0001 | | | 0.8989 |
| Female | 28.4 | 34.0 | | 33.9 | 33.8 | |
| Male | 71.6 | 66.0 | | 66.1 | 66.2 | |
| Age | | | <0.0001 | | | 0.3334 |
| 18-44 years | 2.4 | 5.1 | | 5.2 | 5.0 | |
| 45-64 years | 31.2 | 42.6 | | 41.0 | 42.3 | |
| 65 years and above | 66.3 | 52.3 | | 53.7 | 52.7 | |
| Race/Ethnicity | | | 0.0060 | | | 0.9700 |
| White | 74.8 | 75.4 | | 75.6 | 75.4 | |
| Black | 9.0 | 9.7 | | 9.5 | 9.7 | |
| Hispanic | 8.8 | 8.3 | | 8.3 | 8.3 | |
| Others (Pacific islander, Native Americans, Asians) | 7.5 | 6.6 | | 6.7 | 6.7 | |
| Comorbidity | | | | | | |
| Diabetes Mellitus | 46.7 | 39.6 | <0.001 | 45.9 | 46.9 | 0.27 |
| Chronic kidney disease | 31.3 | 14.4 | <0.001 | 30.5 | 31.8 | 0.12 |
| Coronary artery disease | 95.0 | 94.7 | 0.16 | 95.3 | 95.6 | 0.42 |
| Congestive heart failure | 39.9 | 20.6 | <0.001 | 38.9 | 39.7 | 0.37 |
| Atrial fibrillation | 23.2 | 11.7 | <0.001 | 22.1 | 21.7 | 0.55 |
| Grouped Charlson comorbidity index | | | <0.0001 | | | 0.974 |
| 0 | 1.8 | 5.0 | | 4.9 | 4.9 | |
| 1 | 13.1 | 29.0 | | 28.3 | 28.5 | |
| 2 | 85.1 | 66.0 | | 66.8 | 66.6 | |
| Patient Location of Residence | | | 0.0002 | | | 0.378 |
| Metro | 83.1 | 81.2 | | 81.8 | 81.3 | |
| Non-metro | 16.9 | 18.8 | | 18.2 | 18.7 | |
| Insurance type | | | <0.0001 | | | 0.8916 |
| Public | 76.3 | 64.5 | | 65.2 | 64.9 | |
| Private | 20.7 | 30.5 | | 29.8 | 30.2 | |
| Uninsured | 3.1 | 5.0 | | 4.9 | 5.0 | |

Impact of chronic thrombocytopenia on CTO-PCI

| | | | | | | |
|--------------------|------|------|---------|------|------|--------|
| Hospital Region | | | <0.0001 | | | 0.804 |
| Northeast | 15.4 | 18.0 | | 18.4 | 17.9 | |
| Midwest | 23.8 | 22.4 | | 22.1 | 22.4 | |
| South | 41.6 | 42.4 | | 42.4 | 42.4 | |
| West | 19.2 | 17.3 | | 17.1 | 17.3 | |
| Hospital Bed size | | | <0.0001 | | | 0.8109 |
| Small | 12.1 | 14.5 | | 14.7 | 14.4 | |
| Medium | 29.1 | 29.8 | | 29.9 | 29.8 | |
| Large | 58.8 | 55.7 | | 55.4 | 55.8 | |
| Hospital type | | | <0.0001 | | | 0.8490 |
| Rural | 3.9 | 5.5 | | 5.3 | 5.5 | |
| Urban non-teaching | 21.5 | 23.4 | | 23.5 | 23.3 | |
| Urban teaching | 74.6 | 71.1 | | 71.3 | 71.2 | |
| Hospital Control | | | 0.0059 | | | 0.7542 |
| Government | 7.8 | 8.7 | | 9.0 | 8.7 | |
| Not-for-profit | 76.7 | 74.9 | | 74.9 | 75.0 | |
| For profit | 15.6 | 16.4 | | 16.1 | 16.4 | |

Abbreviations: CT, chronic thrombocytopenia; CTO, chronic total occlusion; PCI, percutaneous coronary intervention; US, United States. Data presented as mean + standard deviation or n (%).




Figure 2. Forest plot illustrating the patient level and clinical factors that independently predicted HRU. Abbreviations: AKI, acute kidney injury; CTO, chronic total occlusion; DM, diabetes mellitus; HRU, High Resource utilization; PCI, percutaneous coronary intervention; PPM, permanent pacemaker. Data presented as mean + standard deviation, median (IQR), or n (%).

95% CI = 0.062-0.313; $P = 0.003$); the presence of 2 or more comorbidities compared to none ($b = 0.483$; 95% CI = 0.2109-0.757; $P = 0.001$); and high illness severity index ($b = 0.707$; 95% CI = 0.682-0.733; $P < 0.001$) (**Figure 2**).

In the adjusted GLM model, the presence of CT during CTO PCI was associated with higher procedural cost ($b = 0.129$; 95% Confidence Interval (CI) = 0.107-0.151; $P < 0.001$). Relative to its absence, CT during CTO PCI was associated with approximately \$18,000 more in total hospital charges (Population Average Treatment Effect (PATE) estimate = +\$18,297.98; 95% CI = \$15,101.33-\$21,494.63, $P < 0.001$).

Patient-level characteristics associated with total charges included race, residence, and illness severity. Compared to non-Hispanic whites, Non-Hispanic Blacks were associated with lower total charges ($b = -0.059$; 95% CI =

-0.096 -0.022; $P = 0.002$). In contrast, Hispanic ($b = 0.123$; 95% CI = 0.078-0.168; $P < 0.001$), and other races ($b = 0.076$; 95% CI = 0.028-0.123; $P = 0.002$) were associated with higher total charges, relative to Non-Hispanic Whites. Total charges were also higher for patients in metropolitan areas than non-metropolitan areas ($b = 0.077$; 95% CI = 0.044-0.110; $P < 0.001$). Illness severity was also associated with higher total charge ($b = 0.381$; 95% CI = 0.367-0.395; $P < 0.001$).

Hospital-level factors associated with higher total charges included a location in the West region, compared to the Northeast ($b = 0.211$; 95% CI = 0.147-0.274; $P < 0.001$), and medium ($b = 0.120$; 95% CI = 0.073-0.166; $P < 0.001$) and larger ($b = 0.172$; 95% CI = 0.128-0.216; $P < 0.001$) bed size, compared to small bed size. On the other hand, total charges were lower in the Midwest, compared to the Northeast ($b = -0.112$; 95% CI = -0.167--0.056; $P < 0.001$) and

Impact of chronic thrombocytopenia on CTO-PCI




Figure 3. Forest plot illustrating the patient level and clinical factors that independently predicted total charges. Abbreviations: AKI, acute kidney injury; CTO, chronic total occlusion; DM, diabetes mellitus; HRU, high resource utilization; PCI, percutaneous coronary intervention; PPM, permanent pacemaker. Data presented as mean + standard deviation, median (IQR), or n (%).

in government ($b = -0.517$; 95% CI = $-0.573--0.462$; $P < 0.001$) and private non-profit ($b = -0.405$; 95% CI = $-0.447--0.364$; $P < 0.001$), compared to for-profit hospitals. Total charges were also lower in rural ($b = -0.200$; 95% CI = $-0.256--0.144$; $P < 0.001$) and urban non-teaching hospitals ($b = -0.065$; 95% CI = $-0.105--0.026$; $P = 0.001$), compared with urban teaching hospitals (**Figure 3**).

Periprocedural complications and clinical outcomes

Before applying propensity weights, CTO-PCI with CT patients had higher in-hospital mortality when compared to the CTO-PCI without CT patients (9.13% vs. 2.50%, $P < 0.001$). Vascular complication was higher in the CTO-PCI patients (2.12%, $P < 0.001$), while that in the CTO-PCI without CT patient was 0.91%, $P < 0.001$. There was higher use of mechanical circulatory support in the CTO-PCI with CT group compared to

the CTO-PCI without CT group (5.29% vs. 1.07%, $P < 0.001$). Placement of permanent pacemakers was higher in the CTO-PCI with CT group, compared to the CTO-PCI without CT group (1.51 vs. 0.52%, $P < 0.001$). Acute kidney injury (AKI) was 35.18% ($P < 0.001$) in the CTO-PCI with CT cohort, while the AKI rate in the CTO-PCI without CT cohort was 13.84% ($P < 0.001$). The use of dialysis, in terms of weight percentage, was 4.47% ($P < 0.001$) in the CTO-PCI with CT cohort, while in the CTO-PCI without CT group, it was 1.29% ($P < 0.001$). There was no difference in stroke rate between the two groups, **Table 2**.

Following the application of propensity score weights as shown in **Table 3**, CT was more likely to be associated with in-hospital mortality in subjects following CTO PCI compared to those without CT, with population average treatment effect (PATE) of 1.02, $P < 0.001$. CT was associated with high use of mechanical circulatory

Impact of chronic thrombocytopenia on CTO-PCI

Table 2. In-hospital outcomes of study population stratified by CT status before application of propensity weights

| Variable | CTO-PCI with CT (n = 7090) | CTO-PCI without CT (n = 209,815) | P-value |
|--------------------------------|-------------------------------|-------------------------------------|---------|
| | Weighted % | Weighted % | |
| In hospital mortality | 9.13 | 2.50 | <0.001 |
| Vascular complication | 2.12 | 0.91 | <0.001 |
| Mechanical Circulatory Support | 5.29 | 1.07 | <0.001 |
| Stroke | 0.12 | >0.01 | 0.3940 |
| PPM placement | 1.51 | 0.52 | <0.001 |
| AKI | 35.18 | 13.84 | <0.001 |
| Dialysis | 4.47 | 1.29 | <0.001 |

Table 3. Association between chronic thrombocytopenia and in-hospital outcomes among patients undergoing PCI following propensity score weighting

| Outcomes | PATE (Percentage point difference) | 95 Confidence Interval | P-value |
|--------------------------------|------------------------------------|------------------------|---------|
| In-Hospital Mortality | 1.03 | 0.61-1.45 | <0.001 |
| Vascular Complication | 0.25 | -0.02-0.51 | 0.0677 |
| Mechanical Circulatory support | 1.31 | 0.99-1.64 | <0.001 |
| Stroke | -0.12 | -0.17--0.07 | <0.001 |
| PPM Placement | 0.98 | 0.64-1.31 | <0.001 |

Note: Reported PATE represents the average difference in the predicted probability of outcomes for CT and non-CT patients nationally. Each in-hospital outcome was modeled using a GLM with binomial distribution and a log link. Each model adjusted for all covariates listed in **Table 1**, including survey year and illness severity index.

support following CTO PCI with a population average treatment effect (PATE) of 1.31, $P < 0.001$. CT was also associated with a higher placement of permanent pacemakers compared with those without CT following CTO PCI with a population average treatment effect (PATE) of 0.98, $P < 0.001$.

Discussion

Major findings

The significant findings of this analysis of CTO patients following PCI are as follows: 1. Chronic thrombocytopenia was associated with high healthcare resource utilization, adjudicated as prolonged length of stay greater or equal to 7, or discharge to non-home settings following CTO PCI. 2. Chronic thrombocytopenia was associated with increased hospitalization costs, the surrogate of total charges standardized to the value of the dollar in 2018 when compared to patients without chronic thrombocytopenia. 3. Chronic thrombocytopenia was

predictive of adverse clinical outcomes, including in-hospital mortality and periprocedural complications, compared to those without chronic thrombocytopenia.

CTO PCI is a complex and high-risk procedure in patients with inherent high bleeding risks, such as those with chronic thrombocytopenia. The current practice guideline recommends a balanced consideration of bleeding with ischemic risks

in these high-risk patients [16]. Unfortunately, patients with chronic thrombocytopenia are mostly excluded from most randomized controlled clinical trials, including Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) trial, the Platelet inhibition, and patient Outcomes (PLATO) trial, the cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition (CHAMPION) trials [17-19]. Ayoub K et al. recently showed in a large retrospective propensity analysis that patients with CT were at higher risk of hospitalization, including a higher risk of in-hospital mortality [10]. Impact of chronic thrombocytopenia on healthcare resource utilization and cost is lacking. The current study addresses this critical question in a large, propensity-weighted analysis of CTO patients following PCI.

Chronic thrombocytopenia was as high as 3.3% in all patients undergoing CTO PCI. This is slightly higher than the incidence in Denmark, Sweden, and Norway [20], underscoring the

Impact of chronic thrombocytopenia on CTO-PCI

need to assess the impact of this common entity, chronic thrombocytopenia, on healthcare resource utilization and cost while optimizing care for CTO patients undergoing PCI.

The clinical benefits of CTO revascularization by PCI are inconsistent. In a recent large meta-analysis, Khan et al. reported lower long-term mortality and cardiac deaths in the CTO-PCI group compared to OMT. However, this apparent clinical benefit was driven by the recruited observational studies, while the included randomized control trials (RCT) showed no significant differences in major adverse cardiac events, including myocardial reinfarction, stroke, or repeat PCI [21]. The plausible explanation for this inconsistency of the benefits of these CTO RCTs is related to the low enrollment number of CTO patients, resulting in the trials being underpowered to show any benefit PCI [22-25]. There was also a high crossover rate exacting selection bias [22-25].

Despite these inconsistencies in clinical benefits as demonstrated by these CTO RCTs, expert consensus guideline recommends CTO PCI for symptomatic relief of angina [26]. Therefore, in CTO patients with Chronic thrombocytopenia, in whom there may be a likelihood of adverse events, there is a need to carefully select patients whose revascularization is likely to provide symptomatic relief while mitigating bleeding. In this analysis utilizing propensity weights, patient and hospital-level variables were homogeneously distributed between the cohort with CT and the group without CT following CTO PCI. One important variable that may have contributed to the adverse events, including high resource utilization, costs, and other clinical outcomes, including in-hospital mortality observed in the CTO-PCI with CT group, maybe operator-dependent variables, including techniques and skill, which is not available in an administrative database like the NIS.

Operator-dependent variables that may affect clinical outcomes may include the use of microcatheter to optimize exchanges and guidewire manipulation [26, 27], antegrade wiring, antegrade dissection and reentry [28], and the retrograde approach [28]. Intracoronary imaging may also mitigate the risk of adverse events [29-32], including healthcare resource utilization, costs, and in-hospital mortality. RCTs test-

ing these operator-dependent variables are desperately needed.

Limitations

This study, like all retrospective observational analyses, has limitations. These limitations help put the study's findings and conclusions into perspective in generalizability to other populations. The NIS is an administrative database subject to the effect of measured and unmeasured confounders. Statistical methods such as propensity-matching tools eliminated most of these confounders. Despite these propensity-matching techniques utilized in this study, we could not eliminate the effect of unmeasured confounders that might have contributed to this study's reported results and findings.

Secondly, we could not stratify the analysis based on the severity of CT. The granular data points, including laboratory results, are unavailable in the NIS database. Hence, studies such as this one, whose findings are based on ICD-10-CM codes, can be challenging. Third, the NIS database was prepared by trained coding specialists after reviewing inpatient-level and hospital-level records for both reporting and reimbursement purposes by the Center for Medicare and Medicaid Services. Therefore, the data are subject to potential oversights in documentation and coding in preparing this nationwide registry. However, NIS may be plagued by coding errors. Despite these limitations, the large number of patients studied provides valuable data in this under-studied thrombocytopenic CTO population following PCI.

Conclusion

In this propensity-weight analysis of patients undergoing chronic total occlusion percutaneous coronary intervention, patients with CT are at higher risk of high resource utilization, worse clinical outcomes, and higher costs when compared to those without CT, within the confines of the limitations of this retrospective study. High-fidelity studies are needed to validate these findings and elucidate strategies to mitigate adverse outcomes in this population.

Disclosure of conflict of interest

None.

Impact of chronic thrombocytopenia on CTO-PCI

Address correspondence to: Dr. Sheriff N Dodoo, Georgia Heart Institute, Northeast Georgia Medical Center, 743 Spring Street NE, Gainesville, GA 30501, USA. Tel: 408-391-2050; E-mail: sheriff.dodoo@gmail.com

References

- [1] Davì G and Patrono C. Platelet activation and atherothrombosis. *N Engl J Med* 2007; 357: 2482-94.
- [2] Aukrust P, Waehre T, Damås JK, Gullestad L and Solum NO. Inflammatory role of platelets in acute coronary syndromes. *Heart* 2001; 86: 605-6.
- [3] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW and Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 64: e139-e228.
- [4] O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ and Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; 61: e78-e140.
- [5] Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhilb SR and Topol EJ; CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. *Circulation* 2010; 121: 2575-83.
- [6] McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM and Harrington RA. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. *Circulation* 1999; 99: 2892-900.
- [7] Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T, Tamai H, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S, Dangas G, Mehran R, Abizaid A, Moses JW, Leon MB and Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. *Circulation* 2005; 112: 2530-7.
- [8] Bagnall A and Spyridopoulos I. The evidence base for revascularisation of chronic total occlusions. *Curr Cardiol Rev* 2014; 10: 88-98.
- [9] Valgimigli M and Costa F. Chronic thrombocytopenia and percutaneous coronary intervention: the virtue of prudence. *JACC Cardiovasc Interv* 2018; 11: 1869-1871.
- [10] Ayoub K, Marji M, Ogunbayo G, Masri A, Abdel-Latif A, Ziada K and Vallurupalli S. Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention. *JACC Cardiovasc Interv* 2018; 11: 1862-1868.
- [11] HCUP. Overview of the National (Nationwide) Inpatient Sample (NIS). Available at: <https://www.hcup-us.ahrq.gov/nisoverview.jsp>. Accessed December 10, 2017.
- [12] Dodoo SN, Okoh AK, Aggarwal T, Osman AF, Nkansah E, Oseni A, Odiete O and Egolom U. Disparities in health and healthcare: impact of race on resource utilization and costs following transcatheter edge-to-edge repair. *Cardiovasc Revasc Med* 2023; 50: 13-18.
- [13] Dodoo SN, Kwapong YA, Agyemang-Sarpong A, Amoran E, Egolom UO, Ghasemzadeh N, Ramadan R, Henry G and Samady H. Comparative healthcare resource utilization of percutaneous mechanical circulatory support using impella versus intra-aortic balloon pump use for patients with acute coronary syndrome and cardiogenic shock undergoing percutaneous coronary interventions: insights from national inpatient sample. *Curr Probl Cardiol* 2023; 49: 102053.
- [14] Okoh AK, Dhaduk N, Shah AM, Gold J, Fugar S, Kassotis J, Chen C, Lee LY and Russo MJ. Health and healthcare disparities: impact on resource utilization and costs after transcatheter aortic valve replacement. *Innovations (Phila)* 2021; 16: 262-266.
- [15] Dugoff EH, Schuler M and Stuart EA. Generalizing observational study results: applying propensity score methods to complex surveys. *Health Serv Res* 2014; 49: 284-303.
- [16] Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Femes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr,

Impact of chronic thrombocytopenia on CTO-PCI

- Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM and Zwischenberger BA. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022; 145: e4-e17.
- [17] Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM and Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007; 357: 2001-2015.
- [18] James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R and Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial. *Am Heart J* 2009; 157: 599-605.
- [19] Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD and Harrington RA; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med* 2013; 368: 1303-1313.
- [20] Christiansen CF, Bahmanyar S, Ghanima W, Risbo N, Ekstrand C, Stryker S, Acquavella J, Kilpatrick K, Frederiksen H, Nørgaard M and Sørensen HT. Chronic immune thrombocytopenia in Denmark, Sweden and Norway: the Nordic country patient registry for romiplostim. *EClinicalMedicine* 2019; 14: 80-87.
- [21] Khan AA, Khalid MF, Ayub MT, Murtaza G, Sardar R, White CJ, Mukherjee D, Nanjundappa A and Paul TK. Outcomes of percutaneous coronary intervention versus optimal medical treatment for chronic total occlusion: a comprehensive meta-analysis. *Curr Probl Cardiol* 2021; 46: 100695.
- [22] Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, Kang H, Kang SJ, Kim YH, Lee CW, Park SW, Hur SH, Rha SW, Her SH, Choi SW, Lee BK, Lee NH, Lee JY, Cheong SS, Kim MH, Ahn YK, Lim SW, Lee SG, Hiremath S, Santoso T, Udayachalerm W, Cheng JJ, Cohen DJ, Muramatsu T, Tsuchikane E, Asakura Y and Park SJ. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. *Circulation* 2019; 139: 1674-1683.
- [23] Henriques JP, Hoebbers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, Ioanes D, Suttorp MJ, Strauss BH, Barbato E, Nijveldt R, van Rossum AC, Marques KM, Elias J, van Dongen IM, Claessen BE, Tijssen JG and van der Schaaf RJ; EXPLORE Trial Investigators. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI: the EXPLORE trial. *J Am Coll Cardiol* 2016; 68: 1622-1632.
- [24] Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR and Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. *Eur Heart J* 2018; 39: 2484-2493.
- [25] Obedinskiy AA, Kretov EI, Boukhris M, Kurbatov VP, Osiev AG, Ibn Elhadj Z, Obedinskaya NR, Kasbaoui S, Grazhdankin IO, Prokhorikhin AA, Zubarev DD, Biryukov A, Pokushalov E, Galassi AR and Baystrukov VI. The IMPACTOR-CTO trial. *JACC Cardiovasc Interv* 2018; 11: 1309-1311.
- [26] Brilakis ES, Mashayekhi K, Tsuchikane E, Abi Rafeh N, Alaswad K, Araya M, Avran A, Azzalini L, Babunashvili AM, Bayani B, Bhindi R, Boudou N, Boukhris M, Božinović NŽ, Bryniarski L, Bufe A, Buller CE, Burke MN, Büttner HJ, Cardoso P, Carlino M, Christiansen EH, Colombo A, Croce K, Damas de Los Santos F, De Martini T, Dens J, Di Mario C, Dou K, Egred M, ElGuindy AM, Escaned J, Furkalo S, Gagnor A, Galassi AR, Garbo R, Ge J, Goel PK, Goktekin O, Grancini L, Grantham JA, Hanratty C, Harb S, Harding SA, Henriques JPS, Hill JM, Jaffer FA, Jang Y, Jussila R, Kalnins A, Kalyanasundaram A, Kandzari DE, Kao HL, Karpaliotis D, Kassem HH, Knaapen P, Kornowski R, Krestyaninov O, Kumar AVG, Laanmets P, Lamelas P, Lee SW, Lefevre T, Li Y, Lim ST, Lo S, Lombardo W, McEntegart M, Munawar M, Navarro Lecaro JA, Ngo HM, Nicholson W, Olivecrona GK, Padilla L, Postu M, Quadros A, Quesada FH, Prakasa Rao VS, Reifart N, Saghatelian M, Santiago R, Sianos G, Smith E, C Spratt J, Stone GW, Strange JW, Tammam K, Ungi I, Vo M, Vu VH, Walsh S, Werner GS, Wollmuth JR, Wu EB, Wyman RM, Xu B, Yamane M, Ybarra LF, Yeh RW, Zhang Q and Rinfret S. Guiding principles for chronic total occlusion percutaneous coronary intervention. *Circulation* 2019; 140: 420-433.
- [27] Azzalini L, Uretsky B, Brilakis ES, Colombo A and Carlino M. Contrast modulation in chronic total occlusion percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2019; 93: E24-E29.
- [28] Suzuki Y, Tsuchikane E, Katoh O, Muramatsu T, Muto M, Kishi K, Hamazaki Y, Oikawa Y, Kawa-

Impact of chronic thrombocytopenia on CTO-PCI

- saki T and Okamura A. Outcomes of percutaneous coronary interventions for chronic total occlusion performed by highly experienced Japanese specialists: the first report from the Japanese CTO-PCI Expert Registry. *JACC Cardiovasc Interv* 2017; 10: 2144-2154.
- [29] Kim BK, Shin DH, Hong MK, Park HS, Rha SW, Mintz GS, Kim JS, Kim JS, Lee SJ, Kim HY, Hong BK, Kang WC, Choi JH and Jang Y; CTO-IVUS Study Investigators. Clinical impact of intravascular ultrasound-guided chronic total occlusion intervention with zotarolimus-eluting versus biolimus-eluting stent implantation: randomized study. *Circ Cardiovasc Interv* 2015; 8: e002592.
- [30] Tian NL, Gami SK, Ye F, Zhang JJ, Liu ZZ, Lin S, Ge Z, Shan SJ, You W, Chen L, Zhang YJ, Mintz G and Chen SL. Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. *EuroIntervention* 2015; 10: 1409-17.
- [31] Karacsonyi J, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani J, Karatasakis A, Danek BA, Doing A, Grantham JA, Karmaliotis D, Moses JW, Kirtane A, Parikh M, Ali Z, Lombardi WL, Kandzari DE, Lembo N, Garcia S, Wyman MR, Alame A, Nguyen-Trong PK, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S and Brilakis ES. Use of intravascular imaging during chronic total occlusion percutaneous coronary intervention: insights from a contemporary multicenter registry. *J Am Heart Assoc* 2016; 5: e003890.
- [32] Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, Tian N, Lin S, Lu Q, Wu X, Li Q, Liu Z, Chen Y, Qian X, Wang J, Chai D, Chen C, Li X, Gogas BD, Pan T, Shan S, Ye F and Chen SL. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. *J Am Coll Cardiol* 2018; 72: 3126-3137.